RxDoctor Payments Data

Kathryn Harshman

Family · Olympia, WANPI 1952537706

Payments from drug & device makers

$2,503in general payments, 2019–2025

Across 87 payments — averaging $28.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$413
  • AbbVie$386
  • Phathom Pharmaceuticals, Inc.$271
  • Lilly USA, LLC$257
  • Novo Nordisk$244
  • Boehringer Ingelheim$176
  • plus $757 from 13 others

What the payments were for

  • Food & beverage$2,503100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,503 in reported general payments places this provider in the 90th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$3,407
Medicare patients
33
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide34$37,501
JardianceEmpagliflozin20$31,962
EliquisApixaban11$17,121
XareltoRivaroxaban11$13,772
Trijardy XrEmpaglifloz/Linaglip/Metformin11$6,551
Fentanyl16$4,169
Albuterol Sulfate HfaAlbuterol Sulfate56$1,942
Atorvastatin Calcium140$1,571
Celecoxib12$1,473
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$1,400
Gabapentin39$1,159
Omeprazole54$1,127
Montelukast Sodium50$1,087
Levothyroxine Sodium79$937
Ondansetron OdtOndansetron17$808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Trijardy Xr$176$38,51331 claims
Lilly USA, LLCMounjaro$257$37,50134 claims
PfizerEliquis$22$17,12111 claims
Johnson & JohnsonXarelto$20$13,77211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,706 family providers in Washington.

Other family in Olympia

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →